Insights & Discussion
High intake of magnesium from foods is linked to a significant decrease in the odds of developing reflux oesophagitis and Barrett's oesophagus.
The study involved participants who were cases of oesophageal adenocarcinoma, Barrett's oesophagus, reflux oesophagitis and population-based controls, all gathered from throughout Ireland between 2002 and 2005. Each participant completed a 101-item Food Frequency Questionnaire (FFQ). The association between dietary intakes of magnesium, calcium and the ratio of calcium to magnesium on the risk of oesophageal adenocarcinoma, Barrett's oesophagus and reflux oesophagitis was analysed using unconditional logistic regression analysis, adjusting for potential confounders.
In terms of results, participants consuming the highest amounts of magnesium from food considerably reduced their odds of reflux oesophagitis and Barrett's oesophagus when compared to those consuming the smallest amounts. This protective effect of magnesium was even more noticeable when the intake of calcium to magnesium was low. However, no significant associations were found between magnesium intake and the risk of oesophageal adenocarcinoma.
Discover Related Insights
Alginate, as a treatment option for laryngopharyngeal reflux, is equally effective as proton pump inhibitors and may serve as a potential alternative treatment.
2022 European Archives of Oto-Rhino-Laryngology Magnesium alginate versus proton pump inhibitors for the treatment of laryngopharyngeal reflux: a non-inferiority randomized controlled trial Pizzorni N, Ambrogi F, Eplite A, Rama S, Robotti C, Lechien J, et al.
Randomised Controlled Trial Alginate GERD Magnesium
Researchers employed a non-inferiority randomized controlled trial with fifty participants, all of whom exhibited laryngopharyngeal symptoms. They were divided into two treatment groups; one group received the alginate suspension Gastrotuss in three daily doses, while the other was administered Omeprazole once daily. The Reflux Symptom Index and Reflux Finding Score were used to measure the severity of symptoms both before the treatment and after the two-month treatment period.
It was found that both groups had similar Reflux Symptom Index and Reflux Finding Score values initially. After the two-month treatment, both groups demonstrated significant decrease in these indices, suggesting that the symptoms and signs of laryngopharyngeal reflux were significantly reduced, regardless of the treatment given. The difference between the changes in both Reflux Symptom Index and Reflux Finding Score from the two groups was found to be insignificant, thereby indicating that the effectiveness of Alginate is non-inferior to Proton Pump Inhibitors.